安立玺荣 is an innovative immunotherapy new‑drug developer committed to R&D for cancer, immune and neurological disease treatments. The company provides products including Alzheimer’s drugs and antibody biologics. It recently announced completion of a financing round totaling nearly RMB 100 million equivalent in USD‑denominated funds. The financing was supported by three dollar funds. The company said the round reflects international and domestic investors' recognition of its scientific innovation and execution capabilities. The report was published by DoNews citing IT桔子. Elixiron is developing therapeutics across cancer, neurological diseases and inflammatory disorders with a focus on reverse-translational immunotherapy approaches. The company operates in San Francisco, Taipei and Shanghai and was founded in 2017 under CEO and Chairman Hung-Kai Chen. It intends to use the Series A-1 funds to advance phase 1 trials of two pipeline candidates and to take three immuno-oncology assets toward IND applications. Pipeline highlights include EI-1071, an orally available, potent CSF1R inhibitor currently in a phase 1 trial and supported by an Alzheimer’s Association Part the Cloud‑Gates Partnership Grant, and EI-001, a fully human antibody targeting immuno-modulatory pathways in vitiligo and chronic hepatitis B. The executive team includes Pandelakis Koni (Executive VP of R&D) and Carrie Duan (Executive VP of Clinical Development).

Total raised

$41M

Funding rounds

2

Latest round

Equity

Latest activity

Mar 2024